- Annexon Inc (NASDAQ:ANNX) announced topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy (GA).
- ANX007 was not statistically significant compared to pooled sham, the comparator, at 12 months in patients with geographic atrophy.
- In every-month dosing, the GA lesion area changed about 6.2% from baseline (p=0.526), 1.3% (p=0.896) in the every-other-month group, and a 3.7% reduction was observed in the pooled patient population (p-value=0.673).
- Patients in the monthly treatment group showed a 72% reduction in the risk of 15-letter loss (p=0.006), and patients in the every-other-month treatment group showed a 48% reduction in the risk of 15-letter loss (p=0.064).
- Patients in the pooled treatment group showed a 59% reduction in risk of >15-letter loss (p=0.008).
- ANX007 was generally well tolerated as both a monthly and every-other-month treatment.
- Annexon said ANX007 was “generally well-tolerated,” noting there were three cases of endophthalmitis or inflammation on the inner shield of the eye, but they were found to be administration-related, not treatment-related.
- The six-month off-treatment follow-up period of the ARCHER Phase 2 trial is ongoing, and Annexon plans to report the final results following the study conclusion.
- Price Action: ANNX shares are 23.60% lower at $3.95 during premarket trading on the last check Thursday.
FDA Pushes Review Date For Ascendis Pharma’s Hormone Disorder Candidate By Three Months
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to hypoparathyroidism.
